Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Vaccine. 2012 Jun 6;30(26):3975-81. doi: 10.1016/j.vaccine.2011.12.022. Epub 2011 Dec 14.
Human parainfluenza virus type 3 (HPIV3) is an important cause of lower respiratory tract illness in children, yet a licensed vaccine or antiviral drug is not available. We evaluated the safety, tolerability, infectivity, and immunogenicity of two intranasal, live-attenuated HPIV3 vaccines, designated rHPIV3-N(B) and rB/HPIV3, that were cDNA-derived chimeras of HPIV3 and bovine PIV3 (BPIV3). These were evaluated in adults, HPIV3 seropositive children, and HPIV3 seronegative children. A total of 112 subjects participated in these studies. Both rB/HPIV3 and rHPIV3-N(B) were highly restricted in replication in adults and seropositive children but readily infected seronegative children, who shed mean peak virus titers of 10(2.8) vs. 10(3.7)pfu/mL, respectively. Although rB/HPIV3 was more restricted in replication in seronegative children than rHPIV3-N(B), it induced significantly higher titers of hemagglutination inhibition (HAI) antibodies against HPIV3. Taken together, these data suggest that the rB/HPIV3 vaccine is the preferred candidate for further clinical development.
人副流感病毒 3 型（HPIV3）是导致儿童下呼吸道疾病的重要病原体，但目前尚无获得许可的疫苗或抗病毒药物。我们评估了两种鼻内、减毒活的 HPIV3 疫苗的安全性、耐受性、传染性和免疫原性，这两种疫苗分别命名为 rHPIV3-N(B)和 rB/HPIV3，它们是 HPIV3 和牛副流感病毒 3 型（BPIV3）的 cDNA 衍生嵌合体。这些疫苗在成年人、HPIV3 血清阳性儿童和 HPIV3 血清阴性儿童中进行了评估。共有 112 名受试者参与了这些研究。rB/HPIV3 和 rHPIV3-N(B) 在成年人和血清阳性儿童中复制受到高度限制，但容易感染血清阴性儿童，血清阴性儿童的病毒载量峰值分别为 10(2.8)和 10(3.7)pfu/mL。尽管 rB/HPIV3 在血清阴性儿童中的复制受到限制比 rHPIV3-N(B)更为明显，但它诱导了针对 HPIV3 的更高滴度的血凝抑制（HAI）抗体。总的来说，这些数据表明 rB/HPIV3 疫苗是进一步临床开发的首选候选疫苗。
Zotero 插件